No Data
Hong Kong stocks move | CANSINOBIO (06185) rises over 5%. The restructured three-in-one polio vaccine has been approved by the National Medical Products Administration to conduct clinical trials.
CANSINOBIO (06185) rose more than 5%, as of the time of writing, it increased by 5.66%, trading at 40.15 Hong Kong dollars, with a transaction amount of 18.2289 million Hong Kong dollars.
Hong Kong Stock Morning Report | The Hong Kong stock market is set to undergo significant changes as LINEKONG establishes a division to accelerate its layout in WEB3 and RWA.
① The Hong Kong Stock Exchange has released a discussion paper on shortening the settlement cycle for the Hong Kong stock spot market. ② AMD announced that it will resume exports of AI chips to China. ③ At the State Council executive meeting, a report was given on regulating the competitive order in the New energy Fund industry. ④ The six-seat version of the MODEL Y L from Tesla has been listed in the new vehicle directory of the Ministry of Industry and Information Technology.
The recombinant spine polio vaccine developed by CANSINOBIO (06185) has received clinical trial approval in China.
CANSINOBIO (06185) announced that the trivalent spinal cord polio vaccine (Sf-RVN cells) developed by the company...
Express News | CanSino Biologics Inc.: The recombinant trivalent poliovirus vaccine (Sf-RVN cells) has received approval for clinical trials.
Express News | CanSino Biologics Inc.: The trivalent oral poliovirus vaccine has obtained the drug clinical trial approval notification.
[Brokerage Focus] BOCOM INTL: The current valuation of the Hong Kong stock market's innovative drug Sector remains attractive.
Jinwu Financial News | BOCOM INTL believes that the valuation of the current Hong Kong stock innovative drug sector remains attractive: 1) The forward P/S ratio of leading innovative pharmaceutical companies is basically in line with the historical average since the bear market, though slightly higher than comparable companies in the US stock market, but the revenue growth expectations are also far superior to the latter; 2) Currently, the leading Hong Kong stocks have a P/S ratio of about 3 times at the peak of their revenue, with some companies only around 2 times, lower than the average 4 times in the US stock market; 3) In the first half of 2025, domestic investors continued to increase their positions through the Stock Connect, but foreign institutions' Hold Positions in innovative drugs are at a low point. Regarding the evolution direction of innovative drugs going overseas, the institution observes the following trends: 1) The industry has further derived new types such as NewCo.